Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235232 | 0.89 | CYP2D6 (0.59) | DHCR7CYP2D6CYP1A2MAPTMEN1 | |
| SCHEMBL6863028 | 0.89 | CYP2D6 (0.59) | DHCR7CYP2D6CYP1A2MAPTMEN1 | |
| SCHEMBL3235228 | 0.89 | CYP2D6 (0.59) | DHCR7CYP2D6CYP1A2MAPTMEN1 | |
| SCHEMBL8425188 | 0.82 | ALDH1A1 (0.56) | CYP2D6CYP1A2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6881853 | 0.82 | ALDH1A1 (0.56) | CYP2D6CYP1A2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8879797 | 0.81 | CYP2D6 (0.66) | DHCR7CYP2D6CYP1A2MAPTMEN1 | |
| SCHEMBL20594955 | 0.79 | CYP2D6 (0.59) | DHCR7CYP2D6CYP1A2MAPTMEN1 | |
| SCHEMBL10175759 | 0.78 | DHCR7 (0.73) | DHCR7PTGDR2PTGDRMEN1KMT2A | |
| SCHEMBL16080246 | 0.78 | DHCR7 (0.73) | DHCR7PTGDR2PTGDRMEN1KMT2A | |
| SCHEMBL7466566 | 0.77 | ALDH1A1 (0.49) | DHCR7CYP2D6CYP1A2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623903-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-8143285-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8143285-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20090105274-A1 | Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105274-A1 | Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1932839-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105274-A1 | Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity | PTGDR, CYSLTR1, CNR1 | DHCR7 710/4885CYP2D6 512/4885PTGDR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.